Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Q4 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript

Feb 27, 2024 / 01:30PM GMT
Release Date Price: $10.63 (+9.70%)
Operator

Good day and welcome to the Arcutis Biotherapeutics 2023 Fourth Quarter and Full Year financial results conference call. (Operator Instructions) Once again, please be advised that today's conference is being recorded. I would now like to hand the call over to Derek Cole, Arcutis Investor Relations. Please go ahead.

Derek Cole
Arcutis Biotherapeutics Inc - IR

Thank you, Andrew. Good morning, everyone, and thank you for joining us today to review 2023 financial results and a business update slides for today's call are available on the investor section of the Arcutis website.

On the call today, we have Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and John Smither, Chief Financial Officer.

I'd remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. So we encourage you to review all the company's filings with the Securities and Exchange Commission,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot